Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Freudenstadt – page 35

721 clinical trials in Freudenstadt, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Freudenstadt at a glance
721
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

721 trials in Freudenstadt

Open in trial search

Study of BI 690517 and empagliflozin combination for protection of heart and kidneys in patients with chronic kidney disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Study of Atezolizumab with Lenvatinib or Sorafenib vs Lenvatinib or Sorafenib alone in Unresectable Hepatocellular Carcinoma after Atezolizumab and Bevacizumab

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Breast cancer+2

Not recruiting

Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Celcuity Inc.

Long‑term safety and tolerability of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps: an extension study

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Obesity

Not recruiting

Study of KAI-9531 in Adults With Obesity or Overweight and Weight-Related Health Problems Without Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:HRS 9531
  • Sponsor:Kailera Therapeutics Inc.

Ovarian cancer

Not recruiting

Phase 3 Study of INCB123667 versus investigator's choice of chemotherapy drug combination in patients with platinum‑resistant ovarian cancer and cyclin E1 overexpression

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:INCB123667
  • Sponsor:Incyte Corp.

Diabetic retinopathy+1

Not recruiting

A study to evaluate the safety and effectiveness of ANXV in patients with diabetic retinopathy or retinal vein occlusion

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ANXV
  • Sponsor:Annexin Pharmaceuticals AB (publ)

Efficacy and Safety Evaluation of Odevixibat in Pediatric Biliary Atresia Post-Kasai Hepatoportoenterostomy: A Double-Blind, Randomized, Placebo-Controlled Trial

Investigational
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Odevixibat
  • Sponsor:Ipsen Pharma

Plasma cell myeloma

Not recruiting

Efficacy and Safety Evaluation of Belantamab Mafodotin Versus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Glaxosmithkline Research & Development Limited

A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Multiple sclerosis

Not recruiting

A Study Comparing Two Forms of Ocrelizumab Given Under the Skin in Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

A Study Comparing Telisotuzumab Adizutecan to Trifluridine, Tipiracil, and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Freudenstadt

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical studies focusing on hormone receptor-positive HER2-negative breast cancer, exploring combination therapies with endocrine treatment approaches.

  • Advanced/Metastatic Breast Cancer
  • Hormone Receptor Studies
  • Digital Side Effect Management

Research aims to evaluate treatment effectiveness and patient outcomes through systematic monitoring and assessment.

02 Biliary Tract Cancer Studies

Groundbreaking research investigating advanced biliary tract cancers through combination therapy approaches using immunotherapy and chemotherapy.

  • First-line Treatment Assessment
  • Combination Therapy Safety
  • Multicentre Clinical Evaluation

The research focuses on evaluating novel treatment combinations to improve patient outcomes in advanced disease stages.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.